Andere Sprachen PMV Pharmaceuticals, Inc.

Aktien

A2QCB3

US69353Y1038

PMVP

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
1,8 ^USD	+1,69 %		-0,28 %	-41,94 %

12.04.	PMV PHARMACEUTICALS, INC. : Jefferies & Co. behält seine Kaufempfehlung bei	ZM
27.03.	PMV Pharmaceuticals, Inc. PMV Pharmaceuticals gibt die Verabreichung des ersten Patienten in der globalen tumordiagnostischen Phase-2-Studie PYNNACLE für Rezatapopt bei TP53 Y220c-positiven soliden Tumoren bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	27.03.
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	27.03.
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer	18.03.
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer	18.03.
North American Morning Briefing : Stock Futures -2-	06.03.
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights	29.02.
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference	26.02.
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway	18.01.
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%	18.01.
PMV Pharmaceuticals Names Michael Carulli as CFO; Phase 2 Trial of Tumor Treatment on Track	05.01.
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development	05.01.
PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes	05.01.
PMV Pharmaceuticals, Inc. Announces Executive Changes	05.01.
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from NASDAQ Biotechnology Index	15.12.
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights	09.11.
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
PMV Pharmaceuticals Says Updated Trial Data Show Cancer Therapy Induces Anti-Tumor Activity; Shares Fall	12.10.23
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation	12.10.23
PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types with TP53 Y220C Mutation	12.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PMV Pharmaceuticals, Inc.

Aktien

A2QCB3

US69353Y1038

PMVP

Andere Sprachen

Filter